BCR and chronic myelogenous leukemia, BCR-ABL1 positive: There is no doubt that identifying targetable vulnerabilities at the core of a cancer’s oncogenicity has yielded remarkable and leaping advances in therapy as with the identification of the BCR-ABL fusion protein in CML and the development of Gleevec.